Oncopharmpod

This episode looks at the combination of PARP inhibitors in combination with androgen receptor pathway inhibitors (ARPi) for untreated advanced prostate cancer. BRCA2 sensitivity > BRCA 1 commentary: https://doi.org/10.1200/JCO.20.02246 Methylphenidate for fatigue in hematologic cancers: https://doi.org/10.1200/JCO-26-00578 Download the Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

ESMO 2026 concluded this past weekend, so this Pod is packed with lots of updates! 1. DeLLphi-305: Maintenance tarlatamab + durvalumab improves OS compared to maintenance durvalumab in extensive stage SCLC. Impressive improvement, but a puzzlingly high rate of dysguesia in the tarlatamab arm that is ~2x what has been reported in tarlatamab monotherapy. 2. Non-ESMO, but related - Lurbinectedin's mono therapy approval for SCLC was was withdrawn following the negative results of the LAGOON trial, which followed the negative results of the ATLANTIS trial. 3. INTerpath-001 was a phase III trial that showed improved recurrence free survival with intismeran autogene + pembrolizumab vs. pembrolizumab in advanced melanoma. This patient-specific mRNA treatment is exciting with more trials planned across solid tumors. 4. Darolutamide may have a role in high-risk prostate cancer following prostatectomy and adjuvant ADT, but longer follow-up (and publication) is likely needed before implementation. 5. VOLGA provides

This week we take a (brief) stop back in time to the beginning of dostarlimab's journey that has ended (for now) in an accelerated approval for rectal cancer that is mismatch repair-deficient or high in micro-satellite instability (MMRd/h-MSI). Download the Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

This week we discuss the recent RCT of blinatumomab-ponatinib in Ph+ Adult ALL and how this regimen compares to previously publishes uses of Blin-Ponatinib in induction treatment. Link: DOI: 10.1056/NEJMoa2606208 Finally, we discuss two recent expanded indications in bladder cancer (nogapendekin alfa inbakicept + BCG) and colon cancer (atezolizumab with FOLFOX for dMMR colon cancer in the adjuvant setting). Download the Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

Tucatinib gets an expanded FDA approval in the 1st-line treatment of HER2(+) metastatic breast cancer based on the results of HER2-Climb05. Pirtobrutinib also gets FDA approved for initial treatment of CLL/SLL (without 17p deletion). Australia makes a bold decision regarding Nivo/Ipi and Pembrolisumab: https://doi.org/10.1200/JCO-26-01340 Download the Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

This week's pod offers a brief review of FGFR inhibitors for cholangiocarcinoma in repsonse to the FDA approval of the latest one, lirafugratinib. LITESPARK-011 demonstrated improved PFS of lenvantinib + belzutifan vs. cabozantinib in the 2nd-line setting of advanced ccRCC. This led to a recent FDA approval. We look at the toxicity, QOL, and OS data known about this combination regimen. Download the Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

Drugs that inhibit signaling via the PI3K pathway (e.g. alpelisib, capivasertib) can cause hyperglycemia. The mechanism of this ADR as well as the implications of which anti-diabetes medications are used in response is discussed. Review article: https://doi.org/10.1177/15347354211073163 Download the Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

This week's podcast discusses a recent meta-analysis on the benefit of a "neutropenic diet" in patients on treatment for cancer. Link: https://doi.org/10.1200/OP-26-00405 The 2026 World Conference on Lung Cancer just wrapped up. We run through the findings of the most notable trials presented at WCLC. Download the Learning Oncology Companion:https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

Press Releases are an increasingly common method to learn about new/upcoming data. What can clinicians learn (and what can't we learn) from these? We read through two examples for just this purpose. Example 1: https://www.amgen.com/newsroom/press-releases/2026/09/imdelltra-in-combination-with-imfinzi-demonstrated-landmark-improvement-in-overall-survival-in-first-line-extensive-stage-small-cell-lung-cancer Example 2: https://aptevotherapeutics.gcs-web.com/news-releases/news-release-details/aptevo-reports-93-clinical-benefit-rate-mipletamig-triplet Possible Help with Drug Shortages: https://www.angelsforchange.org Download the Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

PARADIGM is finally published, so we have more details from this study presented at ASH about HMA/Ven vs. Intensive Chemo if fit patients with AML. Daraxonrasib looks like a promising drug for RAS-mutant NSCLC, too. Download the Oncology Learning Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

This week's pod has everything: 1. DDI information and dosing for daraxonrasib, now FDA approved and commercially available for pancreatic cancer 2. A new standard of care (?) in HER(+) gastric cancers, and more nuance on HER2 positivity. And lots of diarrhea. 3. The largest RCT in primary CNS lymphoma Download the Oncology Learning Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

CELMoDs are here, but are they here to stay? CELMoD/IMiD review article: https://doi.org/10.1080/17474086.2024.2382897 Download the Oncology Learning Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

Overview of renal cell carcinoma Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

This week's episode covers some updates in small cell lung cancer, chemotherapy-induced nausea/vomiting (CINV), SC administration of isatuximab, and Lu-177 vipivotide tetraxetan. Download the Oncology Learning Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

A new drug is approved for ROS1 NSCLC after a prior TKI (with some data in patients after 2 TKIs). Zidesamtinib...easy for you to say. Also, a post hoc analysis of PACIFIC provides some of the best evidence yet of the detrimental effect (?) of PPI use prior to ICI use. Download the Oncology Learning Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

This week's pod covers some brief updates comparing the timelines of the FDA approvals for daraxonrasib vs. enfortuamb vedodin + pembrolizumab, before devoting the rest of the time to the new approval of gedatolisib, a PIK3CA inhibitor, with fulvestrant and maybe palbociclib if you feel like it for metastatic breast cancer in the 2nd line. Oh, in patients WITHOUT PIK3CA mutations. Download the Oncology Learning Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

Did lenalidomide maintenance in multiple myeloma just get limited to 2 years? Endurance Trial, Part 2: https://www.nejm.org/doi/full/10.1056/NEJMoa2600157 Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

We are a decade into the CAR-T era, and what to long term outcomes look like with tisagenlecleucel in B-cell lymphomas? Orca-T is approved, an allogenic cocktail of stem & progenitor cells, Tregs, and then conventional T-cells. Neato. Polar-Go! or PolARGo? And the concept of T-cell "stemless" is intriguing with possibilities: DOI: 10.1056/NEJMcibr2601002 Learning Oncology Companion:https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

This week we discuss a new approval for pabociclib in HER2-positive disease based on the PATINA trial as well as the use of sacituzumab govitecan + pembrolizumab in TNBC, recently approved based on the ASCENT04/KEYNOTED19 trial. And the concept of T-cell "stemless" is intriguing with possibilities: DOI: 10.1056/NEJMcibr2601002 Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

Lots of bite-size updates in this episode. Capitello-281: capivasertib + abiraterone (+ prednisone + ADT) Adjuvant Belzutifan + Pemroblizumab is FDA approved Durvalumab approved with BCG for non-muscle invasive bladder cancer Insightful commentary: https://doi.org/10.1200/JCO-25-02670 Talquetamab + Durvaluamb - a new safety signal? Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm